We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Beactica Announces Drug Discovery Research Collaboration with GE Healthcare and Uppsala University
News

Beactica Announces Drug Discovery Research Collaboration with GE Healthcare and Uppsala University

Beactica Announces Drug Discovery Research Collaboration with GE Healthcare and Uppsala University
News

Beactica Announces Drug Discovery Research Collaboration with GE Healthcare and Uppsala University

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Beactica Announces Drug Discovery Research Collaboration with GE Healthcare and Uppsala University"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Beactica has announced a new research collaboration agreement with GE Healthcare and Uppsala University (Sweden). The collaboration combines Beactica's approach to fragment-based drug discovery and GE Healthcare's Biacore™ technology with enzymology expertise from Uppsala University.

Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore™ surface plasmon resonance instruments and applications for fragment-based drug discovery.

The project also aims to identify high-quality leads against a clincally important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.

"We look forward to deepening our relationship with GE Healthcare and Uppsala University," said Beactica's CEO, Dr Per Kallblad. "The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next - generation applications from GE Healthcare will enable us to stay at the forefront of our field."
Advertisement